Cell Therapeutics (CTIC) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Therapeutics (CTIC)

CTIC 9.090

0.0%

Jun 26 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: zeta1961 who wrote (551)	3/7/2005 4:49:27 PM
From: former_pgs	Read Replies (2) of 946

Unfortunately, Xyotax did not appear to appreciably reduce the incidence of blood count related AEs, which would be a major source of supportive care costs. Although it appears that there is a lower incidence per cycle of treatment, if patients are simply getting more cycles on average with Xyotax, the % of patients requiring supportive care may not be changing appreciably. I believe this topic on blood count related AEs was briefly discussed by Bianco last week. In that respect, combating neutropenia with Epogen is still a greater cost burden on the system than special tubing. Also we need to keep in mind that these patients are still sitting in for a carbo regimen. >Regarding alopecia and it not being enough to compel patients/oncologists to use something that shows equivalency? I think a single phone call or visit to an oncology department can answer that more to your satifaction than I ever could..< If it was up to me I'd let the clinics decide the cost / benefit trade-off that is appropriate. However, for CTIC the stock, the plight of patients is not always sufficient to get the various agencies moving in the ways that we would like them to.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next